
MASH Drugs Raise Urgency for Earlier Diagnosis: Rohit Loomba, MD
Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.
Earlier identification of patients with metabolic dysfunction–associated steatohepatitis (MASH) fibrosis has become more urgent now that treatments are available, and automating Fibrosis-4 index (FIB-4) calculations in electronic health records and using magnetic resonance (MR)–based tests where they are available could help primary care find those patients, said Rohit Loomba, MD, MHSc, director of the MASLD Research Center and chief of the Division of Gastroenterology and Hepatology at the University of California San Diego.
In part 2 of the interview with The American Journal of Managed Care® (AJMC®), Loomba discussed whether the MASH Resolution Index could be used to monitor treatment response outside of specialty settings, how obesity affects the accuracy of noninvasive tests, and what an ideal screening pathway and risk stratification approach for nonspecialists could look like.
This interview has been edited for clarity.
AJMC: Your team developed the MASH Resolution Index, which combines imaging and blood-based markers. Could a composite tool like this be adapted for longitudinal monitoring in primary care, or does it need to stay in specialty or trial settings?
Loomba: I think in certain primary care settings, it could be utilized. For example, in Japan and South Korea, parts of India, a lot of MR [magnetic resonance] is available. They are using MRI-based tests in their routine clinical practice. Depending on the cost for these tests and the availability of an MR scanner, this could be prioritized, and this would probably be the best response indicator.
We showed that the MASH Resolution Index is better than FAST [FibroScan-AST], which is another biomarker that you can use on AST [aspartate aminotransferase], liver stiffness on FibroScan, and CAP [controlled attenuation parameter] on the FibroScan machine.1 It's not as good as the MR, but it can still give you a reasonable idea about improvement or MASH resolution on histology. I think more and more awareness of these MRI-based biomarkers in primary care would be good, because they can identify patients who are responding to treatment, identify patients who need treatment, and also look for treatment response, particularly as they start using some of the drugs that are approved for stage 2 and stage 3 fibrosis, such as resmetirom [Rezdiffra; Madrigal Pharmaceuticals] or semaglutide [Wegovy; Novo Nordisk],2,3 and then they're using other GLP-1 [glucagon-like peptide 1] analogs, such as tirzepatide [Zepbound, Mounjaro; Eli Lilly],4 and look for treatment response in their patients using these MRI-based biomarkers.
AJMC: You mentioned the approved treatments, semaglutide and resmetirom. With both now available, does earlier diagnosis take on more urgency? Does treatment eligibility mainly sharpen the case for better noninvasive testing at the point of primary care?
Loomba: I think this makes for an important case that we need to identify those patients that have the disease so they don't progress to cirrhosis. Once they develop cirrhosis, reversal will be very difficult, and the risk of dying from liver disease also increases, so our window of opportunity is MASH stage 2 or 3. Both of these drugs are available now, so if we can identify those patients who are at high risk and then use noninvasive tests such as MRE [MR elastography], FibroScan, ELF [enhanced liver fibrosis], or FibroSpect II, and identify them, then we can either start them on treatment or refer them for treatment.
AJMC: Looking at these noninvasive tests across different patient populations, what have we learned about their accuracy in populations like those with obesity or advanced age? Are they still reliable? How does that work?
Loomba: The ultrasound-based tests are more commonly available and more utilized in clinical practice, but as the body mass index [BMI] goes above 35 kg/m², the MR tests are much better than them, because they have higher accuracy. We typically will utilize MR elastography in that setting. FibroScan would also help, but it'll just overestimate liver fibrosis in the setting of obesity, and particularly morbid obesity. But MR elastography would be your gold standard in that setting, and I would argue that it's even better than doing a liver biopsy assessment, because liver biopsy itself has its own subjectivity and also inter-reader and intra-reader variability that occurs with it.
With MR elastography, you can standardize your assessment, and it could be automated using AI software now. That has really improved its utility in clinical practice. FibroScan is also useful, but it becomes less precise in the setting of higher BMI, particularly above 35 kg/m².
AJMC: Looking at the FIB-4 calculation and flagging patients, how do electronic health records need to be redesigned to automate that calculation and the flagging of those patients without adding to documentation burdens?
Loomba: I think the FIB-4 dot phrase is commonly used in our clinic. We developed it, and we use it in Epic, so I think Epic can standardize that. That can be used across the board. Then you could think about some sort of pop-up that comes up and leads to an automatic second-level test for anybody with elevated FIB-4, 1.3 or higher. Then, particularly in patients with diabetes who are of a certain age—say 45 or 50 years old—they should all get a liver stiffness assessment as a one-time test in their lives. That's something that one could also consider, particularly if they have overweight or obesity. Because having obesity and type 2 diabetes increases your risk for having both MASH or MASLD and fibrosis pretty significantly.5
AJMC: If costs were not a barrier, what do you think the ideal, scalable MASH screening pathway would look like from a primary care visit to a confirmed diagnosis?
Loomba: If the cost was not an issue, then based upon our research, the most accurate test would be MRI PDFF [proton density fat fraction] with MR elastography to screen at the level of population and then move forward. The other possibility is to develop an ultrasound-based quantitative test for fat and fibrosis. You could improve something upon a FibroScan by developing those tests as well.
The other possibility is developing better blood-based biomarkers, and those could be a combination of lipidomic and fibrosis biomarkers combined. A lot of work is being carried out in that domain using cell-free DNA-associated biomarkers and lipidomic-associated biomarkers. I think there's still a lot of work that needs to be done, but if we were looking for the best test currently, if cost were not an issue, it would be MRI PDFF with MRE.
AJMC: How do you think risk stratification algorithms need to evolve so that nonspecialists can safely decide who needs to go on to treatment versus who can actually be managed with lifestyle intervention alone?
Loomba: I think if you just go with the liver stiffness assessment on either FibroScan or MRE, that's pretty easy. We've set those guidelines,6 and we are refining those. ELF could be used. An ELF cutoff point of 9.2 or higher would identify someone you would think about treatment or who has significant fibrosis. I think those could be applied.
There are other tests, like NIS2+ and NIS4, that are coming along, and those could be utilized as well, such as FibroSpect II, and then cell-free DNA-based testing. I think having multiple blood as well as imaging-based tests available and then utilizing them based upon the availability and access to a patient and also to a physician might be the way to move forward.
References
- Loomba R, Daniel PCN, Amangurbanova M, et al. Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy. Hepatology. 2026;83(4):907-914. doi: 10.1097/HEP.0000000000001396
- Joszt L. FDA approves resmetirom, first treatment for NASH with liver fibrosis. AJMC. March 14, 2024. Accessed October 26, 2026.
https://www.ajmc.com/view/fda-approves-resmetirom-first-treatment-for-nash-with-liver-fibrosis - Klein HE. FDA approves semaglutide for MASH with fibrosis. AJMC. August 18, 2025. Accessed October 26, 2026.
https://www.ajmc.com/view/fda-approves-semaglutide-for-mash-with-fibrosis - Loomba R, Hartman ML, Lawitz EJ, et al; SYNERGY-NASH investigators. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299-310. doi:10.1056/NEJMoa2401943
- Azar M. Diabetes and obesity can damage the liver to the point of failure. UMass Chan Medical School. August 21, 2024. Accessed October 29, 2026.
https://www.umassmed.edu/news/articles/archives/2024/08/diabetes-and-obesity-can-damage-the-liver-to-the-point-of-failure/ - Wilson MP, Shaheen A-A, Leung V, et al. Summary of guidelines for identifying and risk-stratifying patients with metabolic dysfunction-associated steatotic liver disease: a primer for family physicians. Diagnostics (Basel). 2026;16(12):1854. doi:10.3390/diagnostics16121854
Related to this article








